P3 Health Partners Swung to Profit and Beat EPS by $5.17 — Is PIII Stock a Buy at $10?

TradingKey - P3 Health Partners Q1 2026: EPS +$0.32 vs -$4.85 estimate. Medical margin jumped from $49 to $231 per member. 2026 EBITDA guidance raised to $20–$60M. Lake Street target raised to $14. PIII at $10.

P3 Health Partners (NASDAQ: PIII) delivered a Q1 2026 report on May 14 that stands out as one of the biggest EPS surprises of the 2026 earnings cycle, by any yardstick. Wall Street had forecast a loss of $4.85 per share; instead, P3 posted a profit of $0.32, a $5.17 surplus. The company also saw medical margins per member per month leap from $49 to $231. P3 then lifted its adjusted EBITDA full-year 2026 forecast to $20 million to $60 million.

The share price spiked more than 42% in evening trading. From $10.01, PIII has surpassed the 2.0 Fib extension off the $3.56 pivot, with the RSI at 61 and room for additional upside. This is a classic higher-risk, higher-reward turnaround stock that is now reflected in the figures.

Q1 2026 Report, The EPS Surprise and What the Jump in Medical Margins Means

The EPS beat of $5.17 against a $4.85 consensus loss is no rounding difference or an unusual accounting event, it reflects a shift in the basic unit economics of P3 Medicare Advantage operations. The real highlight of the report isn’t EPS but medical margin per member per month, which rose to $231 in Q1 2026 from $49 the year prior.

That is a 371% growth in margin per patient and it is mostly the result of 3 operational shifts:

• a tighter provider panel that focuses on the better producers
• improved coding/risk adjustment that captures acuity and drives up the risk payments
• tighter utilisation that limits care that isn’t necessary

The business was at the bottom of the guidance at revenue of $386.4 million, less than Wall Street forecast, however the margin picture is far more important. P3 posted an adjusted EBITDA of $25.8 million, vs. negative in prior quarters, the proof that profitability has turned a corner. Management described Q1 as a “meaningful turning point” after two years of restructuring, comments that echo the back-to-back beats and raises.

For full-year 2026, P3 updated its forecast for adjusted EBITDA to $20 million to $60 million, a midpoint of $40 million, and revenue of $1.5 billion to $1.65 billion. Lake Street Capital raised its target from $4 to $14 and maintains its Buy rating, a level that is 40% higher than the current share price.

Debt Swap and Why the Balance Sheet Repair Is as Big an Issue as the Earnings

On May 15, the day after earnings, P3 entered into an agreement with its largest shareholder and debt investor to swap its debt for equity. The deal converts some of P3’s debt into stock, lowering the company’s leverage and improving its balance sheet. For a business that has been burning capital through a multi-year turnaround, balance sheet risk is at least as relevant as operational progress to the investment.

In a capitated Medicare Advantage plan, the company must absorb medical costs first and collect on risk adjustment at a later date, so liquidity and debt capacity are essential, more than simply financial indicators.

The debt swap is another major step in reducing that existential risk. Though P3 still has significant debt on its books, and the ability to generate enough cash-flow to handle it will be critical to managing, it is a signal that the biggest creditor believes in the turnaround and prefers taking stock in the company rather than a dollar payment. When the largest creditor and the shareholders are pulling on the same rope, the structural dynamics are more positive than in any quarter of EPS.

P3 Health Partners (NASDAQ: PIII) technicals, Fib 2.0 breakout at $9.52, RSI 61

The 2H NASDAQ chart shows PIII punching above the Fib 2.0 line of $9.52 from $3.56, with strong green impulse bars. It is resting at $10.01 above the ascending channel midline and the MA50/100 convergence at $8.87 to $9.09, with the purple MA trailing above.

P3 Health Partners (NASDAQ: PIII) Price Chart - Source: Tradingview

The RSI at 61.42 is in the green, and is positive on prior pullbacks. It is not in the danger zone. Next resistance is $10.17 to $11.77, followed by $14.36. Initial support is at $8.89 to $7.57.

BUY ABOVE 10.20, HOLDING THE 2.0 FIB BREAKOUT

• Target 1: $11.77, the next Fib extension level
• Target 2: $14.36, target from Lake Street
• Stop loss: Close below $8.89, the midline of the channel

What Was the Outcome of P3 Health Partners First Quarter 2026 Earnings Release?

P3 Health Partners first quarter 2026 GAAP EPS print was positive $0.32 compared to a consensus estimate of negative $4.85 for a $5.17 earnings surprise. Q1 2026 Revenue was $386.4 million, slightly below estimates. Q1 2026 Adjusted EBITDA was positive $25.8 million compared to prior year negative print. Q1 2026 Medical margin per member per month improved from $49 to $231 year over year thanks to network concentration, improved risk adjustment performance and tighter utilization management. P3 Health Partners raised its full year 2026 Adjusted EBITDA guidance to $20 to $60 million ($40 million midpoint). Lake Street Capital raised its price target to $14 (Buy) from $4.

What Is P3 Health Partners and What Is Its Business Model?

P3 Health Partners is a physician-led population health management company focused on Medicare Advantage patients. It operates a capitated, value-based care model: the company partners with independent physicians and provider groups to manage the full spectrum of patient care, taking on financial risk in exchange for the opportunity to generate savings when care delivery improves patient outcomes and reduces unnecessary costs. P3 Health Partners business model requires operational excellence (risk adjustment, network management, utilization management, etc.), which explains the Q1 2026 4.7X improvement in medical margin per member per month from $49 to $231.

Should PIII Stock Be Bought at $10 After the First Quarter 2026 Earnings Release?

PIII stock has a high risk / high reward profile. First quarter 2026 earnings beat, positive medical margin per member per month, raised full year 2026 Adjusted EBITDA guidance, and successful debt exchange represents the first inflection point after years of losing money for P3 Health Partners. Lake Street Capital’s $14 price target is for 40% upside from current levels.

Fibonacci 2.0 breakout over $9.52 with RSI 61 is positive, bullish divergence, and long PIII stock above $10.20 price target $11.77 / $14.36, stop loss $8.89. Continued debt burden, execution risk, Medicare Advantage regulation risk, and negative history makes P3 Health Partners a position-size stock, not a size-up stock, at $10 today.

Bottom Line

P3 Health Partners first quarter 2026 earnings report was the largest EPS surprise of the 2026 earnings season with a positive $0.32 first quarter 2026 GAAP EPS compared to a negative $4.85 earnings estimate. Q1 2026 Medical margin per member per month at $231 compared to $49 year ago is not a one-time occurrence, it is the end result of a two-year period of operational restructuring. Debt exchange reduces the balance sheet risk for P3 Health Partners.

The Lake Street Capital price target of $14 assumes this quarter’s positive print is the first in a string of positive quarters for P3 Health Partners. At $10 per share, the Fibonacci 2.0 breakout over $9.52 is still in play with ample RSI room for appreciation and a long position above $10.20 targeting $11.77 / $14.36 presents the best risk / reward for a healthcare turnaround stock.